BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29737371)

  • 1. Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis.
    Nikfar S; Saiyarsarai P; Tigabu BM; Abdollahi M
    Rheumatol Int; 2018 Aug; 38(8):1363-1383. PubMed ID: 29737371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anakinra for rheumatoid arthritis.
    Mertens M; Singh JA
    Cochrane Database Syst Rev; 2009 Jan; (1):CD005121. PubMed ID: 19160248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and adverse effects of anakinra in treatment of rheumatoid arthritis: a systematic review.
    Bedaiwi MK; Almaghlouth I; Omair MA
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7833-7839. PubMed ID: 34982445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G; Bresnihan B; Bear MB; McCabe D;
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anakinra for rheumatoid arthritis: a systematic review.
    Mertens M; Singh JA
    J Rheumatol; 2009 Jun; 36(6):1118-25. PubMed ID: 19447938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W; Jobanputra P; Barton P; Burls A
    Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.
    Bresnihan B
    Semin Arthritis Rheum; 2001 Apr; 30(5 Suppl 2):17-20. PubMed ID: 11357167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
    Nixon R; Bansback N; Brennan A
    Rheumatology (Oxford); 2007 Jul; 46(7):1140-7. PubMed ID: 17478472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
    CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
    Fleischmann RM; Schechtman J; Bennett R; Handel ML; Burmester GR; Tesser J; Modafferi D; Poulakos J; Sun G
    Arthritis Rheum; 2003 Apr; 48(4):927-34. PubMed ID: 12687534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
    Quartier P; Allantaz F; Cimaz R; Pillet P; Messiaen C; Bardin C; Bossuyt X; Boutten A; Bienvenu J; Duquesne A; Richer O; Chaussabel D; Mogenet A; Banchereau J; Treluyer JM; Landais P; Pascual V
    Ann Rheum Dis; 2011 May; 70(5):747-54. PubMed ID: 21173013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist.
    Bao J; Yue T; Li T; He DY; Bao YX
    Int J Rheum Dis; 2016 Apr; 19(4):370-6. PubMed ID: 24798350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis].
    Botsios C; Sfriso P; Furlan A; Ostuni P; Biscaro M; Fiocco U; Todesco S; Punzi L
    Reumatismo; 2007; 59(1):32-7. PubMed ID: 17435840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis.
    Bao J; Yue T; Liu W; Zhang Q; Zhou L; Xu HJ; Dai SM
    Clin Rheumatol; 2011 May; 30(5):697-701. PubMed ID: 21221689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.